Table 1.
Clinical and Demographic Profile of Both Groups.
| COVID-19 (n = 53) | Control (n = 30) | P-value | |
|---|---|---|---|
| Age, year (median [IQR])1 | 42.3 (25 - 69) | 37.9 (21 - 55) | 0.78 |
| Sex, n (%)2 | |||
| Males | 16 (30.2) | 8 (26.7) | |
| Females | 37 (69.8) | 22 (73.3) | 0.80 |
| Race, n (%)2 | |||
| White | 42 (79.2) | 24 (80.0) | 0.99 |
| Black | 9 (16.9) | 5 (16.7) | |
| Asian | 2 (3.7) | 1 (6.7) | |
| BMI, kg/m2 (median [IQR])1 | 27.8 (19.2 - 46.0) | 26.4 (20.8 - 34.8) | 0.37 |
| Years of studying, (median [IQR])1 | 14.3 (11 - 21) | 14.8 (10 - 22) | 0.78 |
| Any pre-existing comorbidities n (%)2 | |||
| Cardiovascular disease3 | 16 (37.2) | 12 (40.0) | 0.47 |
| Lung disease4 | 12 (22.6) | 7 (23.3) | 0.99 |
| Type 2 Diabetes | 15 (28.3) | 9 (30.0) | 0.99 |
| Hematological disease | 4 (7.5) | 2 (6.7) | 0.99 |
| Hepatic disease | 2 (3.7) | 0 (0) | 0.53 |
| Renal disease | 1 (1.9) | 1 (6.7) | 0.99 |
| Socio-economic status | |||
| Family income ($)(median [IQR])1 | 412.0 (0 - 986.0) | 421.7 (0 - 986.0) | 0.68 |
| Class I, n (%) | 9 (16.9) | 6 (20.0) | 0.77 |
| Class II, n (%) | 12 (22.6) | 8 (26.7) | 0.79 |
| Class IIIa, n (%) | 10 (18.9) | 5 (16.6) | >0.99 |
| Class IIIb, n (%) | 14 (26.4) | 6 (20.0) | >0.99 |
| Class IVabc, n (%) | 8 (15.1) | 5 (16.6) | >0.99 |
| Neurological evaluation | |||
| HADS (median [IQR])1 | 10.0 (1.0 - 18,0) | 9.0 (2.0 - 21.0) | 0.45 |
| NSA (median [IQR])1 | 241.8 (224 - 241) | 242.9 (233 - 244) | 0.89 |
| MRC (median [IQR])1 | 56 (52 - 60) | 60 (58 - 60) | 0.47 |
| PCFS (median [IQR])1 | 1.5 (0 - 3) | 0 |
IQR: interquartile range; Class I: professionals, administrators and managers, higher-grade; Class II: professionals, lower-grade, and higher-degree technicians; Class IIIa: routine non-manual employees, higher-grade; Class IIIb: routine non-manual employees, lower-grade; Class IVabc: small proprietors and employers, and self-employed workers; BMI: body mass index; HADS: Hospital Anxiety and Depression Scale; PCFS: post-COVID-19 functional status scale; NSA: Nottingham sensory assessment; MRC: Medical Research Council scale; 1: Mann-Whitney U test; 2: X2 test. 3 – COVID-19 group: hypertension (n = 12), congestive heart failure (n = 1), and atrial fibrillation (n = 3). Control group: Hypertension (n = 9), congestive heart failure (n = 1), and atrial fibrillation (n = 2). 4 - COVID-19 group: obstructive sleep apnea (n = 6), asthma (n = 4), and chronic obstructive pulmonary disease (n = 2); control group: obstructive sleep apnea (n = 4), asthma (n = 2), and chronic obstructive pulmonary disease (n = 1).